Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK
$599.00
An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “Vaccine effectiveness is the biggest unmet need, and maybe another biggest unmet need is to cover well the AH3 and 2, we are not covering that well and that is very costly among the elderly.”
- “I think the biggest unmet need is that the number of people who are actually vaccinated, if you combine all age groups it is still in the 50% range, and there is a lot of room for improvement.”
Drug Coverage
- Fluad
- Fluzone High dose
- FluMist Quadrivalent
- Flublok
- Flucelvax
- Universal flu vaccines
Overview
An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Strategy At Novartis: Culture Change As The ‘How’ Behind The ‘What’ 
Sign up to the